China’s e-health sector has moved fast. Very fast. When I arrived in Shanghai over 15 years ago, seeing a doctor meant queuing for hours at an overcrowded public hospital. Today, millions of Chinese consumers book a consultation in 30 seconds on their phone. They order prescription drugs with same-day delivery. They track their blood pressure on a smartwatch synced to an app that alerts their physician automatically.
This is not the future. This is China in 2026.
For cosmetics and health-beauty brands, this shift creates a concrete opportunity. Chinese consumers who manage their health digitally are also the consumers buying premium skincare, supplements, and wellness products online. Understanding where they go and what they trust is essential.
What Is e-Health in China?
e-Health in China covers any digital service touching healthcare: online consultations, internet hospitals, e-pharmacies, health apps, AI diagnostics, and connected wearables. The government has actively pushed this sector since 2015 through its “Internet Plus Healthcare” policy, which integrates digital infrastructure with the traditional health system.
The numbers tell the story clearly. China’s online consumer health market reached USD 85 billion in 2025. Analysts project it will hit USD 150 billion by 2029. The broader digital health market, which includes software platforms, hospital digitization, and AI tools, reached USD 94.9 billion in 2025 and is expected to grow at a CAGR of 15.48% through 2034, reaching USD 359.9 billion.
These are not abstract projections. The infrastructure is already built.
The Major e-Health Platforms in China
JD Health: The Dominant Online Pharmacy
JD Health is China’s largest online pharmacy by prescription volume. In the first half of 2025, it posted revenue of 35.29 billion CNY, up 30.17% year-on-year. Its 580 million registered users include a high proportion of urban, health-conscious consumers. These are exactly the people buying premium skincare alongside their vitamins and supplements.
JD Health offers 30-minute medicine delivery in major cities. It also runs an online consultation service, a chronic disease management program, and a growing section of health-beauty and wellness products. If your brand sells anything at the intersection of beauty and health, this platform deserves attention alongside Tmall.
Ping An Good Doctor: AI Meets Primary Care
Ping An Good Doctor is China’s flagship telemedicine platform. It uses AI triage to assess symptoms before connecting patients with one of its licensed physicians. The platform operates 24/7, has built its own online pharmacy, and processes millions of consultations per month.
What brands often miss: Ping An Good Doctor is also an advertising channel. Health-adjacent products, from collagen supplements to dermatologist-tested skincare, can appear contextually when users consult for skin conditions, hormonal issues, or nutritional deficiencies.
Alibaba Health and WeChat Health
Alibaba Health plugs directly into Tmall’s pharmacy section. In 2020, over 250 million users purchased through Tmall’s online pharmacy. That number has grown significantly since then. For cosmetics brands already on Tmall, adding health-positioned SKUs to the pharmacy or wellness sections is a logical extension.
WeChat has quietly become a health management hub. Users book hospital appointments, receive consultation results, file insurance claims, and access their digital health records inside the same app they use to chat with friends and follow brand accounts. WeChat Mini Programs now let brands create health-focused loyalty experiences: skin analysis tools, UV exposure trackers, personalized routine builders. At Cosmetics China Agency, we’ve helped brands build Mini Programs that sit at the junction of skincare and health tracking.
AI Is Rewriting the Consultation Model
In late 2025, China’s government published implementation guidelines for “AI + Healthcare” covering 24 specific application scenarios across clinical diagnostics, patient services, and public health. The AI health market alone is forecast to reach USD 9 billion by 2026.
In practice, this means consumers in China increasingly start their health journey by asking an AI. Platforms like Doubao (ByteDance) and Kimi (Moonshot AI) have added health Q&A features used by millions of users every day. Someone searches for a remedy for dark spots or hair thinning. The AI gives an answer and often suggests products or services.
I’ve seen brands fail because they treated AI search and traditional search as the same thing. They are not. On Doubao or Kimi, responses are conversational and brand mentions depend on how well your product information appears in training data and indexed sources. Building a presence in Chinese health content, on platforms like Xiaohongshu, matters now for your visibility in AI-generated answers.
The Telemedicine Boom and What It Means for 2026
China’s telemedicine market was valued at USD 7.38 billion in 2025. It is expected to reach USD 21.01 billion by 2035, growing at a CAGR of 11.03%. The driver is simple: China has 1.4 billion people and not enough doctors, especially outside Tier 1 cities.
Internet hospitals, which are licensed facilities providing online prescriptions and follow-up care, have multiplied rapidly. By 2025, China had over 3,000 licensed internet hospitals. They can prescribe drugs, refer patients to offline care, and manage chronic conditions remotely.
For health-beauty brands, this creates a specific opportunity. Dermatology is one of the most consulted specialties on telemedicine platforms. When a user gets a diagnosis for eczema, acne, or hyperpigmentation through an internet hospital, they need products. Brands that have built credibility with dermatologists, and that appear in the recommendations ecosystem of these platforms, gain a real advantage over those that only run paid ads on social.
Consumer Behavior Shifts in 2026
Two trends define Chinese consumer behavior in health right now.
First, premiumization in preventive health. Urban consumers aged 25 to 45 are spending more on supplements, functional skincare, and wellness devices. They are not cutting back on health spending. At Cosmetics China Agency, we’ve worked with brands that saw their collagen supplement and vitamin C serum lines outperform standard skincare SKUs on JD Health and Tmall Health. The consumer wants products that work, and they want clinical language to back the claim.
Second, the rise of the silver economy. China’s population is aging. By 2026, over 300 million Chinese are aged 60 or above. This cohort is increasingly digital. Wearable health devices and remote monitoring apps designed for the elderly are among the fastest-growing product categories. Beauty brands that develop anti-aging lines with health-claim positioning, and that market through health channels rather than only fashion-driven social content, are finding a receptive audience.
Douyin and Health-Beauty Commerce
Douyin has become a major health content platform. Doctors, pharmacists, and dermatologists post short videos to millions of followers. This KOL ecosystem around health-beauty is different from lifestyle influencers. Audiences trust medical credibility over aesthetics. A dermatologist recommending a specific sunscreen formula on Douyin converts at higher rates than a celebrity holding the bottle.
Live commerce on Douyin has integrated health consultations directly into shopping streams. Brands like Winona, which positions itself as dermatologist-approved sensitive skin care, have used this format aggressively and built a dominant position in the medical-grade skincare segment. The format works because it collapses the distance between diagnosis and purchase.
Regulations: What Changed and What to Watch
China’s regulatory environment for e-health tightened between 2023 and 2025. The key changes affecting brands:
- Online prescription drug sales are now legal and regulated since the 2019 Drug Administration Law amendment, but platforms must verify prescriptions. This creates a need for brands to work within licensed pharmacy structures.
- Health claims on products sold through internet hospitals must meet standards set by the National Medical Products Administration (NMPA). Vague claims like “improves skin health” are being scrutinized more closely.
- AI diagnostic tools used in clinical settings require regulatory approval. This slows integration but also creates trust for approved platforms.
The brands that do well in this environment prepare their documentation before entry. At Cosmetics China Agency, we’ve worked with brands that spent months trying to reverse-engineer compliance after launch. That approach costs more and takes longer than getting the regulatory groundwork right from the start.
How to Position Your Brand in China’s e-Health Channels
The data is clear: Chinese consumers are managing their health digitally, and they are buying health-adjacent products through the same channels. Here is how to act on this.
Start with clinical positioning. If your product has ingredients backed by research, build that narrative in Chinese. White papers, ingredient explainers, and dermatologist endorsements published on Chinese health platforms carry weight on Xiaohongshu and Douyin, and increasingly in AI search results.
Second, get your products into health-commerce channels. JD Health and Tmall’s pharmacy section require specific documentation but give you access to a consumer actively seeking health solutions. This is a different audience from the fashion-driven buyer on standard Tmall or on WeChat Moments ads.
Third, test Douyin doctor KOL partnerships. Find licensed dermatologists or pharmacists with engaged audiences. Their recommendation credibility outperforms standard influencer content for health-positioned products. Our KOL marketing team identifies and vets these profiles specifically for health-beauty campaigns.
Our digital marketing agency for China specializes in cosmetics brands. Contact us for a free audit of your China strategy.
